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Abstract
A thyroid nodule is a discrete radiologically distinct lesion in the gland paren-
chyma. These are a common finding in the general population, majority being 
diagnosed incidentally during neck imaging. The major clinical relevance lies in the 
fact that 4–6.5% of nodules can be malignant. A thorough clinical evaluation and 
examination should be followed by serum TSH assessment and ultrasonography 
for assessment of size, number, imaging characteristics suggestive of malignancy, 
cervical lymphadenopathy. FNA should be done based on clinical and sonographic 
characteristics. Further choice of management modality and extent of surgery 
should be based on cytopathological findings supplemented by molecular testing if 
available.
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1. Introduction
A thyroid nodule is defined as a discrete radiologically distinct lesion from the 
surrounding thyroid parenchyma. Nodules which are palpable but do not cor-
respond to distinct abnormalities on ultrasound do not fall under this category [1]. 
Clinically they can be identified by the doctor on examination or even noticed by 
the patient themselves. With the increasingly popular use of neck imaging modali-
ties, thyroid nodules are being commonly identified during these imaging studies.
The clinical importance lies in excluding malignancy in a thyroid nodule, assess-
ing functional status, associated with pain at appearance and compressive symp-
toms (if large) and accordingly decide the line of management. The key guidelines 
included to cover this area include
1. The 2015 American Thyroid Association Management Guidelines for Adult 
Patients with Thyroid Nodules and Differentiated Thyroid Cancer.
2. AACE/ACE/AME Task Force on Thyroid Nodules. American Association of 
Clinical Endocrinologists, American College of Endocrinology, and Associ-
azione Medici Endocrinologi medical guidelines for clinical practice for the 
diagnosis and management of thyroid nodules-2016 update [2].
3. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): white paper of 
the ACR TI-RADS Committee [3].
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4. European Thyroid Association guidelines for ultrasound malignancy risk 
stratification of thyroid nodules in adults: The EU-TIRADS [4].
This chapter thus provides a comprehensive coverage of the topic with an 
optimal approach in management of a thyroid nodule.
2. Epidemiology
Thyroid nodules are a common finding in general population. This is likely due 
to the increased use of diagnostic imaging for purposes unrelated to the thyroid. 
The prevalence of thyroid nodules in a population depends on the screening 
method used and the presence of risk factors for nodule development. The preva-
lence of thyroid nodules by palpation was found to be 4.2% in a population-based 
study in Framingham. The prevalence in females and males was 6.4 and 1.5%, 
respectively [5]. Clinically nonpalpable nodules are frequently identified on ultra-
sonography and are termed “incidentalomas.” The prevalence of thyroid nodules as 
detected by high resolution ultrasound can be as high as 67% [6]. The prevalence 
in this Californian study also had an asymmetrical distribution with 72 and 41% 
prevalence in females and males respectively. 22% patients had solitary nodules, 
whereas 45% had multiple nodules. In another Italian study by Bartollota et al., the 
prevalence of thyroid nodules by ultrasonography was 33.1%. Thus it becomes a 
difficult dilemma on what to do with incidentally detected thyroid nodules which 
are not malignant and not well-characterised.
Also the number of detected nodules increases with age, with the highest 
prevalence in the seventh decade. Autopsy studies provide the true prevalence of 
the incidence in a population. An autopsy study in Mayo clinic revealed a prevalence 
of around 50% even in patients with no history of thyroid disease [7, 8]. This makes 
it even more complicated that many individuals would complete their lifespan 
without any intervention for their thyroid nodules.
3. Risk factors
The prevalence of thyroid nodules is 4 times more common in females than in 
males. Gender disparity is postulated to occur secondary to influence of oestrogen 
and progesterone, as demonstrated by increased risk associated with pregnancy 
and multiparity [9]. The prevalence of thyroid nodules increases with age. Nodules 
occur more commonly in areas of iodine deficiency. Cigarette smoking can also 
predispose to development of nodular goitre. This can occur secondary to inhibi-
tion of iodine uptake and organification by thiocyanate, which is derived from 
cyanide in cigarette smoke, hence mimicking iodine deficiency [10]. Obesity has 
also been demonstrated to be associated with increased risk of goitre and thyroid 
nodules [11, 12]. Serum IGF-1, being a potent mitogenic factor, was postulated 
to be associated with development of thyroid nodules. A positive association was 
observed between serum IGF-1 levels and prevalence of thyroid nodules in males 
in a study by Volzke et al. In a study by Ying Jian Liu et al., serum IGF-1 levels were 
not found to be significantly different in patients with hot nodules, cystic cold and 
solid cold nodules. However, in subgroup analysis, patients with thyroid adenoma 
on FNA were found to be having significantly higher serum IGF1 levels compared 
to the control group comprising of healthy adults. However no such association was 
demonstrated in a study by Hsiao et al. [13–15]. On the other hand, alcohol intake 
has been associated with decreased prevalence of goitre and thyroid nodules [16].
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Autoimmune thyroid diseases are commonly associated with thyroid nodules. 
Graves disease is associated with nodules in 10–31% of patients. In a Brazilian 
study, the prevalence of nodules in Graves disease was 27.8%; 19.5% of the nodules 
harboured thyroid carcinomas, yielding an overall malignancy prevalence of 5% 
in patients with Graves disease. Younger age and increased thyroid volumes were 
associated with increased risk for papillary thyroid carcinoma (PTC). This was in 
contrast to other studies where older age was a risk factor for malignancy [17, 18]. 
Small thyroid nodules are also commonly associated with Hashimotos thyroiditis. 
These should be differentiated form pseudonodules resulting from inflammatory 
infiltrate. Despite the concerns, the US Preventive Services Task Force (USPSTF), 
which reviews the effectiveness of screening programs in asymptomatic individu-
als, recommended against screening for thyroid cancer in adults without signs or 
symptoms of the disease [19].
4. Aetiology
Thyroid nodular disease comprises of a wide range of disorders. Colloid nodules, 
cysts and thyroiditis comprise of 80% of cases, whereas benign follicular neoplasms 
and thyroid carcinomas account for 10–15% and 5% cases respectively [20]. These 
causes have been summarised in Table 1.
5. Clinical evaluation
Thyroid nodules can present as anterior neck swelling. Most nodules grow 
very slowly over years. Patients may also present with history of rapid increase 
in size, which can be suggestive of a malignancy, or a haemorrhage into a nod-
ule, especially if associated with pain. Significant sized nodules can result in 
compressive symptoms based on the anatomical structure being compromised. 
Larger nodules can result in compression of underlying structures leading to 
symptoms like dyspnoea, dysphagia, and hoarseness of voice with compression 
of trachea, oesophagus and recurrent laryngeal nerves respectively. Patient 
can also present with thyroid dysfunction. Younger patients with adenoma and 
thyrotoxicosis (Toxic adenoma) tend to present with the classical symptoms of 
thyrotoxicosis like nervousness, weight loss despite increased appetite, tremors, 
palpitations, heat intolerance and sweating. On the other hand, thyrotoxicosis 
in elderly can present with non-specific symptoms like anorexia, atrial fibrilla-
tion, congestive heart failure, and is difficult to diagnose due to lack of classical 
symptoms. A hypothyroid presentation with fatigue, constipation, cold intoler-
ance is more indicative of a diagnosis of autoimmune thyroiditis in patients with 
nodular goitre.






Papillary thyroid carcinoma (PTC)
Follicular thyroid carcinoma (FTC)
Medullary thyroid carcinoma (MTC)
Anaplastic thyroid carcinoma (ATC)
Primary thyroid lymphoma
Metastatic carcinomas (breast, renal, lung, head and neck)
Table 1. 
Aetiology of thyroid nodules.
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Findings suggestive of hyperthyroidism or hypothyroidism should be actively 
elicited during examination. Size of the gland and qualitative and quantitative 
description of palpable nodules and lymph nodes should be noted, including size, 
tenderness, consistency and fixity to surrounding anatomical structures. Smaller 
thyroid nodules <1 cm, and posteriorly or substernally located nodules can be dif-
ficult to palpate, and would be better characterised by imaging techniques.
Increasingly nodules are being detected during neck imaging for other indica-
tions. The clinical importance of diagnosis of thyroid nodules lies in excluding 
malignancy in these patients. 4–6.5% of thyroid nodules can harbour malignancy 
[1]. History of rapid growth of the nodule, hoarseness of voice due to paralysis 
of vocal cords suggests a malignant aetiology. Examination features in such cases 
could include a hard consistency of the nodule, fixation to surrounding structures, 
presence of regional lymphadenopathy or distant metastases. The risk of a nodule 
being malignant increases with extremes of age and with male sex. The frequency 
of malignancy in patients with solitary nodules is not different from nodules seen in 
multinodular thyroid disease [21].
Other risk factors which impart increased risk of malignancy should be enquired 
in all patients. History of prior exposure to radiation for various indications like hae-
matopoietic malignancies and stem cell transplantation, head and neck, mediastinal 
and CNS tumours should be sought, as this increases the likelihood of malignancy in 
thyroid nodules. Familial forms of thyroid cancers should be considered in differential 
diagnosis in the presence of supportive history. Most common form of familial thyroid 
cancers is seen in medullary thyroid carcinomas (MTC). Familial MTC can occur 
either as an isolated problem inherited in an autosomal dominant fashion, or as a com-
ponent of MEN 2A (MTC, primary hyperparathyroidism, pheochromocytoma) MEN 
2B (MTC, pheochromocytoma, ganglioneuromas, Marfanoid habitus, thickened cor-
neal nerves). Familial papillary thyroid carcinoma (PTC) can occur as an autosomally 
dominantly inherited isolated form, or can be a component of Pendred syndrome or 
intestinal polyposis syndromes like Familial adenomatous polyposis (FAP), Gardner 
syndrome and Peutz Jeghers syndrome. Follicular thyroid carcinoma (FTC) can be 
associated with Cowden disease and Bannayan Riley Ruvalcaba syndrome. Carney 
complex type I can be associated with either PTC or FTC, whereas Werner’s syndrome 
can be associated with PTC, FTC or anaplastic thyroid carcinoma (ATC) [22]. Factors 
suggestive of an increased likelihood of malignancy have been summarised in Table 2.
6. Laboratory evaluation
6.1 Serum TSH
The initial evaluation in all patients presenting with a thyroid nodule should 





Compressive symptoms: dyspnoea, dysphagia, hoarseness of voice
Childhood H/O exposure to radiation
Family H/O thyroid malignancies, MEN2, intestinal polyposis 
syndromes







Risk factors for malignancy.
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subclinical or overt hyperthyroidism should be considered. Approximately 10% of 
solitary nodules can be associated with a subnormal TSH. Multinodular goitres, on 
the other hand, are frequently associated with suppressed TSH due to development 
of autonomy in the nodules. Serum free T4 levels and T3 levels should be obtained 
for documentation of hyperthyroidism; the latter may especially be obtained in 
areas with iodine deficiency due to preferential secretion of T3 over T4 in these 
circumstances. Patients with a thyroid nodule and subnormal TSH can be taken for 
a Nuclear Thyroid Scan to document the functional status of the nodule.
6.2 Serum thyroid antibodies
In patients with elevated TSH, anti-thyroid peroxidase (anti-TPO) antibodies 
may be measured which point to a diagnosis of Hashimotos thyroiditis. However, 
positive anti-TPO does not obviate the need for a cytopathological evaluation, as 
a coexisting malignancy needs to be ruled out. A raised or even a normal TSH is 
associated with an increased risk of malignancy, as well as a more advanced stage of 
differentiated thyroid cancer [23, 24].
6.3 Serum thyroglobulin
Thyroglobulin (Tg) is a storage form of thyroid hormones, synthesised by 
thyroid follicular cells. Serum Tg levels are elevated in many benign and malignant 
thyroid disorders. An elevated level of serum Tg cannot differentiate malignancy 
in a thyroid nodule with certainty. Measurement of serum thyroglobulin has a role 
in postoperative monitoring for residual, recurrent or metastatic disease in patients 
with differentiated thyroid cancers.
6.4 Serum calcitonin
Calcitonin is produced by the parafollicular C cells of the thyroid gland and is 
a marker for medullary thyroid cancer (MTC). Basal and pentagastrin stimulated 
serum calcitonin has a role in early diagnosis as well as post-operative monitoring of 
patients with MTC. Serum calcitonin is measured in patients with family history of 
MTC or MEN-2 syndrome. Unstimulated serum calcitonin levels >50–100 pg/ml are 
commonly associated with MTC. There are no recommendations for the routine use 
of calcitonin in evaluation of thyroid nodules in current recommendations.
7. Imaging
7.1 Radionuclide scan
Hyper-functioning thyroid nodules comprise up to 10% of thyroid nodules. 
Currently ATA recommends performing a thyroid radionuclide scan in patients 
with thyroid nodule associated with subnormal TSH. Two radionuclides are 
primarily used for functional evaluation of thyroid nodules: I123 and Tc 99 m 
pertechnetate. Both the radioisotopes are taken up by thyroid follicular cells, but 
only radioiodine is organified and stored within the gland. A thyroid nodule can 
be classified as “hot/hyperfunctioning”, “warm/isofunctioning” and “cold/hypo-
functioning” on scintigraphy. A functioning nodule is nearly always benign. 5% 
of nodules that appear hot or warm on pertechnetate scanning can appear cold on 
radioiodine scanning, up to 30% of which can be malignant [25].
On the contrary, the risk of malignancy in non-functioning nodules is 4–6.5% 
[26–29]. Since malignancy is rarely encountered in hyperfunctioning nodules, 
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further cytological evaluation is not necessary if a corresponding hot nodule is 
identified on scintigraphy.
7.2 Ultrasonography
Ultrasonography has become an indispensable tool for the evaluation of thyroid 
nodules. Ultrasound is easily available, non-invasive and invaluable for dileniation 
and prognostication in these patients. Ultrasound in the hands of an experienced 
sonologist enables accurate identification of size, number of nodules, composi-
tion, echogenicity, margins, presence and type of calcifications, shape if taller than 
wide, vascularity and status of cervical lymph nodes. The pattern of sonographic 
characteristics of a nodule confers a risk for malignancy. Categories of high suspi-
cion nodules are then subjected to invasive modalities like Fine Needle Aspiration 
(FNA) and cytological evaluation is done. Features with the highest specificities 
(median > 90%) are microcalcifications, irregular margins and tall shape, even 
though the sensitivities are significantly low for any single feature.
Ultrasound is also invaluable in assessing the risk of malignancy in lymph 
nodes. Location of the lymph nodes adds to the diagnosis. Malignant nodes are 
more likely to occur in levels III, IV and VI than in level II. PTC tumours arising 
in upper pole of the thyroid may be an exception as they have a propensity to 
demonstrate skip metastases to levels III and II. Size of >1 cm, ratio of long axis to 
short axis (also called as Solbiati index of <2), punctate calcification, presence of 
hyperechogenicity/mixed echogenicity/cystic changes, loss of hilum and peripheral 
hypervascularity are some of the features predictive of malignancy. While periph-
eral vascularity has the highest sensitivity of 86%, punctate calcifications are 100% 
specific for malignant involvement [30, 31]. However, no single sonographic feature 
is adequately sensitive for determining malignant involvement. Sonographically 
suspicious lymph nodes ≥8–10 mm in the smallest diameter should therefore 
undergo FNA to look for evidence of malignant involvement.
Ultrasound Elastography is a novel modality performed with an ultrasound 
machine using an elastography computational module. It provides a measure of tis-
sue stiffness, and is being used for malignancy risk assessment. In a study by Azizi 
et al., thyroid nodule stiffness by elastography was an independent predictor of thy-
roid carcinoma, with a PPV of 36%, comparable to that of microcalcifications. On 
the contrary, in another study by Moon et al., elastography alone or in combination 
with grey scale ultrasound showed an inferior performance compared to grey scale 
ultrasonographic assessment for differentiation of benign and malignant thyroid 
nodules [32]. Guidelines currently do not recommend universal use or widespread 
adoption of ultrasound elastography for malignancy risk assessment.
7.3 CT and MRI neck
Since ultrasound is operator dependent and cannot adequately image deep 
anatomic structures and those acoustically shadowed by bone or air, preoperative 
cross sectional imaging like CT/MRI can be used as an adjunct in patients with clini-
cal suspicion of advanced disease, like patients with an invasive primary tumour, or 
clinically apparent multiple or bulky nodal involvement. These modalities permit 
imaging beyond the routine cervical regions imaged by the ultrasound, like infra-
clavicular, retropharyngeal, parapharyngeal regions and the mediastinum. These 
also aid in preoperative planning to accurately delineate the inferior border, extent 
of laryngeal tracheal, oesophageal or vascular involvement.
Combined ultrasound and CT may have a higher sensitivity for macroscopic 
nodal metastasis detection preoperatively, compared to ultrasound alone [33, 34]. 
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Contrast enhanced CT helps in the accurate delineation of the primary tumour and 
the metastatic disease with the surrounding areas. There exists a small risk of pre-
cipitating hyperthyroidism due to iodine content in the contrast agents. Iodine from 
the IV contrast agents is generally cleared within 4–8 weeks of the scan, as assessed 
by the urinary iodine levels returning to baseline. Hence a waiting period of atleast 
a month is advisable to allow urinary iodine levels to return to normal before mov-
ing forward to the use of diagnostic or therapeutic radioiodine post-operatively. 
There is no evidence to suggest this could translate into adverse outcome for thyroid 
cancer patients currently [31, 35]. MRI is prone to respiration artefacts and can be 
more difficult to interpret by surgeons in the operating room.
7.4 FDG PET
Functional imaging with 18 F – FDG PET is currently not recommended rou-
tinely prior to initial surgery. However, it has been widely accepted as a modality 
for detecting recurrence of differentiated thyroid cancer, particularly in non-iodine 
avid disease. PET avidity has also been shown to be a strong predictor of poor 
outcome in metastatic thyroid cancer [31].
7.5 Guidelines for evaluation, reporting and management of thyroid nodules
Sonographic Scoring systems are used to stratify nodules according to risk 
of malignancy to allow centres for uniform reporting and reduce interobserver 
variability.
The American Thyroid Association (ATA) risk stratifies nodules into high 
suspicion, intermediate suspicion, low suspicion, very low suspicion and benign 
categories based on imaging characteristics. The sonographic features have been 
shown in Figure 1 and the FNA cut-offs have been summarised in Table 3.
Similar to Breast reporting, the American College of Radiology has developed 
a reporting system for thyroid nodules known as Thyroid Imaging Reporting 
and Data System (TIRADS) for risk stratification based on points assigned for 
Figure 1. 
Sonographic characteristics of thyroid nodules (Adapted from ATA guidelines for adult patients with thyroid 
nodules and differentiated thyroid cancer [1]).
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Figure 2. 
The ACR-TIRADS scoring system of reporting for thyroid nodules (reproduced from www.acr.org).
Sonographic 
pattern






High suspicion Solid hypoechoic nodule or solid hypoechoic 
component of a partially cystic nodule with one 
or more of the following
• Irregular margins 
(infiltrative, microlobulated)
• Microcalcifications
• Taller than wider shape
• Rim calcifications with small extrusive soft 
tissue component




Hypoechoic solid nodule with smooth margins, 
without microcalcifications, ETE, or taller than 
wider shape
10–20% ≥1 cm
Low suspicion Isoechoic or hyperechoic solid nodule, or 
partially cystic nodule with eccentric solid areas, 
without microcalcification, irregular margin or 




Spongiform or partially cystic nodules without 
any of the sonographic features described as low, 




Sonographic characteristics and FNA cutoffs of thyroid nodules Adapted from ATA guidelines for adult 
patients with thyroid nodules and differentiated thyroid cancer [1].
9
Thyroid Nodule: Approach and Management
DOI: http://dx.doi.org/10.5772/intechopen.91627
composition, echogenicity, shape, margin and echogenic foci in the nodule. The 
total number of points is then used to classify a nodule into benign (TR1), not suspi-
cious (TR2), mildly suspicious (TR3), moderately suspicious (TR4), and highly sus-
picious (TR5) categories. This system was proposed in a study by Horvath et al., and 
the probability of malignancy was 0, 3.4%, 14% and 87% in categories 2, 3, 4 and 5 
respectively [36]. FNA is not indicated in TR1 and TR2 categories, whereas FNAC 
is advised if nodule size is ≥2.5, ≥1.5 and ≥ 1 cm, respectively, in TR3, TR4 and TR5 
categories, respectively. The details of the scoring system are shown in Figure 2.
Patients with multiple thyroid nodules ≥1 cm should be evaluated similarly as 
delineated above for patients with solitary nodule. Each nodule in a multinodular 
gland carries an independent risk of malignancy, and FNA should be done in 
sequentially based on imaging characteristics. In case of multiple sonologically 
similar low or very low risk pattern nodules, aspiration can be done in the largest 
nodule ≥2 cm, or surveillance can be continued without FNA.
8. Fine needle aspiration (FNA)
FNA is the single most valuable, cost effective and accurate method in the evalu-
ation of a nodular goitre. It has demonstrated a sensitivity and specificity of 65–98 
and 72–100%, respectively [22]. The use of FNA results in fewer surgeries, reduced 
cost of care, while improving the malignancy yield at thyroidectomy [37]. Selection 
of which nodule to subject to FNA is crucial for optimum yield of the procedure. 
This is based on the sonographic criteria and the size cut-offs depending on which 
guideline one follows.
FNA is done as an outpatient procedure under local anaesthesia or no anaesthe-
sia. 23–27 guage needles are used to obtain samples for cytopathology. For nodules 
with a high likelihood of non-diagnostic cytology (>25–50% cystic component) or 
sampling error (difficult to palpate or posteriorly located), ultrasound guided FNA 
is preferred [29].
To address variability in reporting thyroid cytopathology, Bethesda System for 
reporting thyroid cytopathology was introduced in 2007. Cytologic adequacy for 
reporting was defined as presence of at least six groups of well visualised follicular 
cells, each group containing at least 10 well preserved epithelial cells, preferably on a 
single slide. The Bethesda system recognises six diagnostic categories and provides an 
estimation of cancer risk within each category, which has been summarised in Table 4.
Diagnostic category Estimated risk of 
malignancy by 
Bethesda system, %
Actual risk of malignancy in 
surgically excised nodules, % 
median (range)
Non diagnostic or unsatisfactory 1–4 20 (9–32)
Benign 0–3 2.5 (1–10)
Atypia of undetermined significance or 
follicular lesion of undetermined significance 
(AUS/FLUS)
5–15 14 (6–48)
Follicular neoplasm or suspicious for a 
follicular neoplasm (FN/SFN)
15–30 25 (14–34)
Suspicious for malignancy 60–75 70 (53–97)
Malignant 97–99 99 (94–100)
Table 4. 
The Bethesda system for reporting cytopathology: diagnostic categories and risk of malignancy [38].
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PTC, MTC and ATC can be diagnosed by cytopathology preoperatively. However, 
cytopathology cannot differentiate between FTC and follicular adenoma as histo-
pathological findings of vascular and capsular invasion distinguish these entities.
9. Markers and molecular testing
FNA specimens can also be investigated for molecular markers, mutations and 
rearrangements to assess the risk of malignancy, prognosis and decide further 
management strategies in cases of indeterminate cytology.
Thyroglobulin and calcitonin in the washout fluid from FNA of cervical lymph 
nodes can serve as potential markers for metastatic well differentiated thyroid car-
cinoma and MTC respectively. TG levels of <1 ng/ml in the washout fluid is reassur-
ing, with higher levels corresponding to increasing probability of N1 disease. This is 
particularly useful in cases in which lymph nodes are cystic, cases with inadequate 
cytological evaluation and sono-cytological discordance [1].
The 2 most common molecular testing strategies are mutational analysis and 
gene expression analysis (GEC), in which genetic information can be derived from 
the sample obtained in the original fine-needle aspiration.
Mutational analysis involves isolating DNA from thyroid follicular cells in the 
specimen and performing gene sequencing. For example, RET-PTC and AKAP9/
BRAF rearrangements, BRAF mutations can be associated with PTC and ATC of PTC 
origin. PTCs with BRAF mutation tend to be more aggressive, with greater propensity 
for extrathyroidal invasion and a more advanced clinical stage. FTCs are commonly 
associated with PAX8/PPARγ fusion in 20–50% of cases, followed by RAS mutations. 
The presence of markers like calcitonin and RET protein are suggestive of MTC. RET 
mutations are associated with fMTC, MEN2A and MEN 2B [22]. The seven gene 
mutation and rearrangement panel comprising of BRAF, NRAS, HRAS and KRAS 
point mutations, and rearrangements of RET/PTC1 and 3, and PAX8/PPARγ has a 
high specificity of 86–100% and a PPV of 84–100%, but poor sensitivity of 44–100%. 
It is being used as a rule in test for thyroid malignancy. However, while mutations 
in RAS genes (HRAS, KRAS, NRAS) are present in thyroid cancers, they are also 
present in nonmalignant thyroid neoplasms and in noninvasive follicular thyroid 
neoplasm with papillary-like nuclear features (NIFTP), and are therefore less specific. 
Furthermore, if no mutations are found, a thyroid malignancy with a mutation that 
was not assessed could still be present (~4%); therefore, mutational testing may lead 
to both false-negative and false-positive results, especially if RAS mutations are found.
The second type of molecular testing, gene expression classifier (GEC), uses a 
proprietary algorithm to analyse the expression of specific genes, the Afirma gene 
expression classifier (167 GEC), i.e. the mRNA expression of 167 genes, evaluates 
for the presence of a benign gene expression profile, with a high sensitivity of 92% 
and NPV of 93%, but low PPV and specificity of 48–53%. Hence it is used as a rule 
out test to identify benign nodules that do not require surgery. However one needs 
to bear in mind that nodules with a benign GEC result still have a 5% risk of malig-
nancy [28]. MicroRNA analysis is a more recent method for molecular testing for 
which limited data is available.
10. Management
10.1 Toxic adenoma and toxic multinodular goitre
Patients with toxic adenoma and toxic multinodular goitre (Toxic MNG) can be 
managed with either radioactive iodine ablation (RAIA) or surgery with surgery 
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being preferred for Toxic MNG and RAIA for Toxic adenoma. For patients with 
toxic adenoma, the risk of treatment failure is <1% after surgical resection (ipsilat-
eral thyroid lobectomy or isthmusectomy), whereas the risk of persistent hyper-
thyroidism and recurrent hyperthyroidism with radioiodine therapy is 6–18 and 
3–5.5%, respectively. For patients with toxic multinodular goitre, the risk of treat-
ment failure is <1% following surgery (near-total/total thyroidectomy), compared 
with 20% risk of need for retreatment following radioiodine therapy.
Radioiodine therapy may additionally be preferred in the following scenarios:
• Advanced patient age
• Comorbidities with increased surgical risk
• Small goitre size
• RAIU sufficient to allow therapy
• Previously operated or irradiated necks
• Lack of access to a high volume thyroid surgeon
Radioiodine therapy is contraindicated in pregnancy, lactation, coexisting 
thyroid cancer, inability to comply with radiation safety guidelines.
Surgery (near total/total thyroidectomy for multinodular goitre, ipsilateral 
thyroid lobectomy or isthmusectomy for toxic adenoma) can be preferred in the 
following scenarios:
• Symptomatic compression or large goitres >80 g
• Need for rapid correction of the thyrotoxic state
• Substernal or retrosternal extension
• Relatively low uptake of RAI
• Documented or suspected thyroid malignancy
• Large thyroid nodules, especially if >4 cm
• Coexisting hyperparathyroidism requiring surgery
In patients who are poor candidates for either therapies, long term anti-thyroid 
drugs (ATDs) can be considered as an alternative [39].
10.2 Management of thyroid nodule based on FNA findings
If a nodule is found benign on cytology, no further immediate diagnostic studies 
or treatment is required. Infact more than 90% of detected thyroid nodules need 
no intervention because they have no ultrasound features to suggest malignancy or 
because they are cytologically benign.
Nodules with high suspicion pattern on ultrasound can be followed up with a 
repeat ultrasound and FNA within 12 months, whereas nodules with low to inter-
mediate suspicion can have a repeat ultrasound at 12–24 months. If sonographic 
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evidence of growth (>20% increase in atleast two nodule dimensions, with a 
minimal increase of 2 mm, increase in volume by 50%) or appearance of a suspi-
cious sonographic pattern, FNA should be repeated or monitoring continued with 
repeat ultrasound, with repeat FNA in case of continued growth. Nodules with very 
low suspicion pattern can have a repeat ultrasound at ≥24 months if >1 cm, rest do 
not require a routine sonographic follow up. If a nodule has a second benign cytol-
ogy on repeat ultrasound guided FNA, then further surveillance with ultrasound 
is not required. Surgery may be considered in growing nodules >4 cm, presence 
of compressive symptoms or cosmetic concern. There is no role of levothyroxine 
suppression therapy in benign thyroid nodules.
For nodules with AUS/FLUS cytology, repeat FNA and molecular testing may 
be used to supplement malignancy risk assessment in addition to clinical and 
sonographic features. Mutational testing for BRAF in AUS/FLUS samples has high 
specificity, but low sensitivity for cancer. Testing for the seven gene panel of muta-
tions and rearrangements (BRAF, NRAS, KRAS, HRAS, RET/PTC1, RET/PTC3, 
PAX8/PPARγ) offer a significantly higher sensitivity of 63–80%. On the other hand, 
molecular testing using the 167 GEC (gene expression classifier) in AUS/FLUS 
cytology has yielded a sensitivity and NPV of 90 and 95%, respectively, but only 
53% specificity and 38% PPV for cancer. If repeat FNA and molecular testing are 
not performed or both are inconclusive, either surveillance or diagnostic surgical 
excision may be carried out based on clinical and sonographic risk factors and 
patient preference.
If cytology is suggestive of FN/SFN, diagnostic surgical excision is the long-
established standard of care. Clinical, sonographic pattern and molecular testing 
may be used to supplement the malignancy risk assessment. Testing for the seven 
gene panel of mutations in FN/SFN cytology has a sensitivity of 57–75%, specific-
ity of 97–100%, PPV of 87–100%, NPV of 79–86%. Molecular testing with GEC is 
reported to have a 94% NPV, and a 37% PPV in the FN/SFN subgroup. If molecular 
testing is unavailable, a diagnostic surgical excision is the preferred treatment 
modality. No further treatment is required if the histopathology of surgical speci-
men is suggestive of a follicular adenoma. However, if the histopathology is sugges-
tive of FTC, then a completion thyroidectomy may be required.
If the cytology is suspicious of papillary carcinoma (SUSP), surgical manage-
ment is similar to that of malignant cytology, depending on clinical risk factors, 
sonographic characteristics and mutational testing if available. BRAF testing is 
estimated to have 36% sensitivity and 100% specificity, whereas testing with seven 
gene panel is reported to have 50–68% sensitivity, 86–96% specificity, 80–95% 
PPV and 70–75% NPV in this subgroup. On the other hand, GEC testing has a PPV 
(76%) similar to cytology, and a NPV of 85%, hence is not indicated in this cyto-
logical diagnosis. Molecular testing may be done if expected to alter the surgical 
decision making.
For a nodule with initial non diagnostic cytology, repeat FNA should be done 
with ultrasound guidance, and with on-site cytological evaluation if available. If 
the results are repeatedly non diagnostic, surgery should be considered for histo-
pathological diagnosis in the presence of clinical and sonographic risk factors for 
malignancy, or growth of the nodule >20% in two dimensions detected during 
ultrasound surveillance.
Surgical management in cytologically indeterminate nodules (AUS/FLUS, FN/
SFN, SUSP) can be either hemithyroidectomy or near total or total thyroidectomy 
based on clinical risk factors (nodule >4 cm, family history, history of radiation) 
and findings on sonography, cytology and molecular testing.
If cytology is diagnostic of a primary thyroid malignancy, then thyroid sur-
gery is the treatment of choice. The choice of surgery depends on the stage of the 
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differentiated thyroid cancer. In tumours ≥4 cm, or with gross extrathyroidal 
invasion or clinically apparent nodal metastasis or distant metastasis, near total or 
total thyroidectomy is the treatment of choice. Therapeutic central compartment 
neck dissection should accompany the procedure in case of clinical involvement of 
central nodes. Therapeutic lateral neck compartmental neck dissection should be 
undertaken in case of biopsy proven metastatic lateral cervical lymphadenopathy. 
Prophylactic central compartment neck dissection can be considered in cases of 
papillary thyroid carcinoma with advanced primary tumour (T3/T4), or clinically 
involved lateral neck nodes.
For thyroid cancers >1 cm and < 4 cm, with no gross extrathyroidal invasion/
nodal or distant metastasis, either lobectomy or near-total/total thyroidectomy 
can be considered. In tumours <1 cm, without extrathyroidal extension and nodal 
involvement, the initial surgical procedure should be a lobectomy, unless there are 
clear indications to remove the contralateral lobe. Active surveillance can be chosen 
in very low risk tumours like micropapillary carcinoma (tumour ≤1 cm), patients at 
high surgical risk or limited life expectancy [1].
Newer minimally invasive methods like percutaneous ethanol ablation, radiofre-
quency, laser, microwave ablation, and high-intensity focused ultrasound have been 
tried and may be considered for treating clinically relevant benign thyroid nodules 
[40]. Recurrent cystic thyroid nodules with benign cytology can be considered for 
percutaneous ethanol injection (PEI) or surgical excision. Ethanol acts by coagula-
tive necrosis and small vessel thrombosis.
10.3 Management in specific situations: pregnancy
Thyroid nodules may enlarge slightly during pregnancy, though this does not 
imply malignant transformation. Patients with suppressed TSH beyond 16 weeks 
of pregnancy should be monitored until after delivery and cessation of lactation, 
followed by a radionuclide scan to assess the functional status of the nodule if TSH 
is still suppressed.
In euthyroid and hypothyroid patients, FNA should be done if clinically and 
sonographically indicated similar to non-pregnant patients. If PTC is diagnosed by 
cytology during pregnancy, surgery should be considered during pregnancy only if 
there is substantial growth (>20% increase in atleast two nodule dimensions, with 
a minimal increase of 2 mm, increase in volume by 50%) before 24–26 weeks of 
gestation, or if ultrasound reveals cervical nodes suspicious of metastatic disease. 
The surgery should be carried out in second trimester before 24 weeks to minimise 
the risk of miscarriage. If the disease remains stable by mid gestation, or diagnosed 
in second half of the pregnancy, surgery may be deferred until after delivery. As 
higher TSH levels may correlate with a more advanced stage of cancer, thyroid hor-
mone therapy can be initiated if TSH > 2 mIU/L, with a target TSH of 0.3–2 mIU/L 
for the remainder of gestation.
11. Conclusion
Thyroid nodules pose a common clinical problem to physicians and surgeons 
alike. The primary concern in the evaluation of thyroid nodules is exclusion of 
malignancy while bearing in mind that most thyroid nodules are benign. With the 
advent and easy availability of high-resolution ultrasound, reliable of characterisa-
tion is possible while deciding on further testing for FNA. FNA is the single most 
valuable cost effective and reliable investigation for risk stratification, comple-
mented by clinical risk factors. New molecular markers can aid in risk stratification 
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in nodules with indeterminate cytology. Diagnostic surgical excision can be done in 
these patients if associated with high risk clinical and sonographic features. Patients 
with malignant cytology should undergo surgery. Evidence based practices should 
be followed while keeping in mind patient preferences thus giving individualized 
precision medical care for patients with thyroid nodule.
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